FUNPLUS
25.11.2021 20:22:08 CET | Business Wire | Press release
FunPlus, a leading mobile game developer and publisher, and its KingsGroup studio today welcome iconic DC Super-Villain, The Joker, as a new playable hero in State of Survival , the free-to-play strategy game available on both iOS and Android . Licensed by Warner Bros. Interactive Entertainment on behalf of DC, all players who complete the thrilling story campaign will have a limited window to permanently unlock The Joker for their roster.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125006179/en/
As one of the most well-known Super-Villains in pop culture, The Joker makes his State of Survival debut providing gamers and fans of the character an eventful campaign that combines zombies with his infamous maniacal behavior, offering a strategy experience like no other.
“FunPlus is proud of the success of State of Survival and its appeal to other brands in the entertainment space. As we wrap up our crossover with AMC’s The Walking Dead, we’re thrilled to be able to align with DC to incorporate The Joker, one of the most popular characters in entertainment,” said Chris Petrovic, Chief Business Officer of FunPlus. “We are excited to share this new campaign and encourage fans of The Joker to jump into State of Survival today!”
To see The Joker in action and for a glimpse into the storyline, check out the teaser trailer here .
For more information on DC, visit dccomics.com . For more information on FunPlus, visit http://www.funplus.com . For more information on State of Survival, visit https://funplus.com/games/state-of-survival/ .
Find a link to assets HERE
About FunPlus
Founded in 2010, FunPlus is a world-class, independent game developer and publisher headquartered in Switzerland and with operations in China, Japan, Singapore, Spain, Sweden, Russia, and the United States.
As an organization that fosters the best creative and diverse talent in the world, and employs nearly 2,000 people, the company has developed and published games that have ranked in the #1 spot in nearly 70 countries, including State of Survival, King of Avalon and Guns of Glory.
FunPlus studios include KingsGroup, Puzala, Seven Games and Imagendary Studios, each with a focus on developing a unique brand of innovative games for global audiences.
FunPlus is the founder of FPX（FunPlus Phoenix), one of the world's most successful esports organizations, and the 2019 League of Legends World Champions.
About Warner Bros. Interactive Entertainment
Warner Bros. Interactive Entertainment is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information can be found at www.wbgames.com .
About DC
DC is one of the largest English-language publishers of comics and graphic novels in the world and home to some of the most iconic and recognizable characters ever created. As a creative unit of WarnerMedia, DC is charged with strategically integrating its stories and characters across film, television, consumer products, home entertainment, interactive games, and the DC UNIVERSE INFINITE digital subscription service and community engagement portal. For more information visitdccomics.com and dcuniverseinfinite.com .
™ & © DC Comics. ™ & © Warner Bros. Entertainment Inc. (s21)
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom